TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04573543

Intervention type: DIAGNOSTIC_TEST
Intervention: Measurement of serum semaphorin concentrations
Description: Semaphorin concentration will be measured in patient sera by ELISA.

Intervention type: DIAGNOSTIC_TEST
Intervention: Identification of semaphorin gene polymorphisms
Description: Semaphorin genes will be sequenced to identify semaphorin gene polymorphisms associated with NAFLD.

Intervention type: DIAGNOSTIC_TEST
Intervention: Identification of semaphorin gene polymorphisms
Description: Semaphorin genes will be sequenced to identify semaphorin gene polymorphisms associated with NAFLD.
Study: NCT02228967

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SBIRT
Description: SBIRT is an opportunistic approach whereby patients are screened by Health Educators for their alcohol use, and then, taking advantage of a teachable moment, are delivered a brief, motivational intervention matched to their level of risk.
Study: NCT03448445

Intervention type: OTHER
Intervention: Usual care setting
Description: usual care settings without any intervention

Intervention type: OTHER
Intervention: Usual care setting
Description: usual care settings without any intervention
Study: NCT03440502

Intervention type: PROCEDURE
Intervention: spinal anaesthesia
Description: Intrathecal block under strict aseptic conditions will be performed by median approach (L3-4 or L4-5) under sitting position by anesthesiologists . 25 Gauge sprotte spinal needles and 2-3 mLof 0.5% hyperbaric bupivacaine

Intervention type: PROCEDURE
Intervention: spinal anaesthesia
Description: Intrathecal block under strict aseptic conditions will be performed by median approach (L3-4 or L4-5) under sitting position by anesthesiologists . 25 Gauge sprotte spinal needles and 2-3 mLof 0.5% hyperbaric bupivacaine
Study: NCT04640623

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAR-200
Description: TAR-200 will be administered transuretherally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAR-200
Description: TAR-200 will be administered transuretherally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAR-200
Description: TAR-200 will be administered transuretherally.
Study: NCT00655668

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide capsules, 25 mg daily for 21 days in each 28 day cycle
Study: NCT04640623

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetrelimab
Description: Cetrelimab will be administered.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetrelimab
Description: Cetrelimab will be administered.
Study: NCT03145181

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teclistamab (IV)
Description: Participants will receive IV infusion of Teclistamab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teclistamab (IV)
Description: Participants will receive IV infusion of Teclistamab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teclistamab(SC)
Description: Participants will receive SC injection of Teclistamab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teclistamab(SC)
Description: Participants will receive SC injection of Teclistamab.
Study: NCT02637557

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PPI
Description: All participants were taking a standard dose QD PPI (dexlansoprazole, esomeprazole, esomeprazole magnesium, lansoprazole, omeprazole, pantoprazole, pantoprazole sodium sesquihydrate, rabeprazole or rabeprazole sodium) during the study.
Study: NCT01892579

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored Activity Program
Description: TAP is designed to tap into spared or residual abilities and provide an environment supportive of these abilities. Activities are selected that build on preserved capabilities, long-term interests and procedural memory, but which do not tax areas of cognition that are most impaired (e.g., memory, new learning). Activities selected are simplified (1 to 2 vs multiple, complex steps), thereby minimizing errors. The activity environment is set up to provide auditory or tactile cues to facilitate recall and guide initiation and sequencing. By grading activities to match PwD capabilities, the interventionist minimizes demand that may heighten stress (e.g., high functioning individuals are introduced to more goal-directed, multi-step activities, whereas lower functioning individuals are introduced to activities involving repetitive motion (e.g., washing windows, folding towels, placing materials in a bin) and integrate multi-sensory stimulation (e.g., soft music, objects pleasant to touch).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home Safety and Education Program
Description: The control group intervention is designed to control for the nonspecific elements of TAP such as social engagement with PwD and CG which may affect outcomes. It is a fully-structured, nondirective, supportive education approach that conveys empathy, respect and specific disease education elements of which have been tested in other trials. Unlike TAP, this group contains no active elements beyond its nonspecific components, has no long-lasting treatment effects, and no theoretical basis to support an effect on agitation. It is delivered by a trained research team member who uses active listening, open questioning, reflecting back, and summation with CGs.
Study: NCT02776761

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hantaan Vaccine:
Description: DNA Vaccine 2.0 mg/1 mL phosphate-buffered saline

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Puumala Vaccine
Description: DNA Vaccine 2.0 mg/1 mL phosphate-buffered saline

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hantaan/Puumala Vaccine
Description: DNA Vaccine 2.0 mg/1 mL phosphate-buffered saline
Study: NCT02215174

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Rosuvastatin 20mg po x1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Rosuvastatin 20mg po x1
Study: NCT03613350

Intervention type: DIAGNOSTIC_TEST
Intervention: Pad test
Description: 20-minutes pad test and urodynamic study (including uroflowmetry, filling and voiding cystometry, and urethral pressure profile) were conducted to every patient.

Intervention type: DIAGNOSTIC_TEST
Intervention: Pad test
Description: 20-minutes pad test and urodynamic study (including uroflowmetry, filling and voiding cystometry, and urethral pressure profile) were conducted to every patient.

Intervention type: DIAGNOSTIC_TEST
Intervention: Pad test
Description: 20-minutes pad test and urodynamic study (including uroflowmetry, filling and voiding cystometry, and urethral pressure profile) were conducted to every patient.

Intervention type: DIAGNOSTIC_TEST
Intervention: Pad test
Description: 20-minutes pad test and urodynamic study (including uroflowmetry, filling and voiding cystometry, and urethral pressure profile) were conducted to every patient.
Study: NCT01604421

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Thermoregulation-standard care
Description: Standard care without plastic bag. One hour after birth, a blanket will be wrapped around the infant and he/she will receive a wool hat, according to standard practices. The infant's axillary temperature will be monitored for 24 hours or until discharge, whichever comes first.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thermoregulation with plastic bag
Description: One hour after birth, the infant will be placed into a plastic bag up to his/her axillae, and the bag will be folded and taped to itself to prevent it from covering the infant's nose or mouth. A blanket will be wrapped around the infant, and he/she will receive a wool hat. The infant will remain in the bag, which will be changed when soiled, for 24 hours or until discharge, whichever occurs first.
Study: NCT01910766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10
Description: no more details

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clomiphene citrate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clomiphene citrate
Study: NCT01691859

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mepolizumab
Description: 100 mg of mepolizumab will be injected subcutaneously (SC) once every 4 weeks
Study: NCT04550195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986337
Description: Specified Dose on Specified Days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986337
Description: Specified Dose on Specified Days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986337
Description: Specified Dose on Specified Days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986337
Description: Specified Dose on Specified Days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986337
Description: Specified Dose on Specified Days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986337
Description: Specified Dose on Specified Days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986337
Description: Specified Dose on Specified Days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986337
Description: Specified Dose on Specified Days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986337
Description: Specified Dose on Specified Days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986337
Description: Specified Dose on Specified Days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986337
Description: Specified Dose on Specified Days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986337
Description: Specified Dose on Specified Days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986337
Description: Specified Dose on Specified Days
Study: NCT01965041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aflibercept
Description: 2.0 mg intravitreal aflibercept injection is formulated as a sterile liquid to a final concentration of 40 mg/mL aflibercept in 5% sucrose, 10 mM sodium phosphate pH 6.3, 0.03% polysorbate 20, and 40 mM NaClvs. placebo
Study: NCT04550195

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BMS-986337 Placebo
Description: Specified Dose on Specified Days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BMS-986337 Placebo
Description: Specified Dose on Specified Days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BMS-986337 Placebo
Description: Specified Dose on Specified Days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BMS-986337 Placebo
Description: Specified Dose on Specified Days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BMS-986337 Placebo
Description: Specified Dose on Specified Days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BMS-986337 Placebo
Description: Specified Dose on Specified Days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BMS-986337 Placebo
Description: Specified Dose on Specified Days
Study: NCT01848379

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ADT+FD

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: FD
Study: NCT03983122

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic sleeve gastrectomy
Description: Each procedure will be completed with laparoscopy with five trocars. A 36F bougie will used to calibrate the volume of the remnant stomach. Linear gastrectomy will begin 2 cm proximal of the pylor and will continue until the gastroesophageal junction. According to the intraoperative decision and experience of the surgeon, endoscopic clips would be used to ensure hemostasis of the stapler line.
Study: NCT00886028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal doxorubicin
Description: Liposomal doxorubicin 60 mg/m2 every 4 weeks for 6 cycles.~Thirty patients with epithelial, sarcomatoid or biphasic histological confirmed diagnosis of MPM from the Instituto Nacional de Cancerología and the Instituto Nacional de Enfermedades Respiratorias were included to receive LD 60mg/m2 plus cisplatin 80 mg/m2 every 4 weeks for 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 80 mg/m2 every 4 weeks for 6 cycles.~Thirty patients with epithelial, sarcomatoid or biphasic histological confirmed diagnosis of MPM from the Instituto Nacional de Cancerología and the Instituto Nacional de Enfermedades Respiratorias were included to receive LD 60mg/m2 plus cisplatin 80 mg/m2 every 4 weeks for 6 cycles.
Study: NCT03122054

Intervention type: PROCEDURE
Group type: OTHER
Intervention: laparoscopic cholecystectomy
Description: First trocar was inserted with Hasson method (Subumbilical 1 cm vertical incision was made and first 10-mm trocar (VersaportTM plus V2, Covidien, USA) inserted under direct vision) and pneumoperitoneum was created with 12 mm Hg pressure. Second 10-mm trocar was inserted from subxyphoid area. Two 5-mm trocars were inserted in the right upper quadrant area. After general intrabdominal exploration, dissection was started to ensure safe-view of Calot triangle. In case of quite tough gallbladder for griping, gallbladder was drained with a gray intravenous cannula. Cystic artery and cystic duct were separately dissected and twice ligated with Endo Clip™ II ML (Covidien, USA). Gallbladder was dissected from liver bed carefully. Gallbladder was taken out from abdomen through the subumbilical incision.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: laparoscopic cholecystectomy
Description: First trocar was inserted with Hasson method (Subumbilical 1 cm vertical incision was made and first 10-mm trocar (VersaportTM plus V2, Covidien, USA) inserted under direct vision) and pneumoperitoneum was created with 12 mm Hg pressure. Second 10-mm trocar was inserted from subxyphoid area. Two 5-mm trocars were inserted in the right upper quadrant area. After general intrabdominal exploration, dissection was started to ensure safe-view of Calot triangle. In case of quite tough gallbladder for griping, gallbladder was drained with a gray intravenous cannula. Cystic artery and cystic duct were separately dissected and twice ligated with Endo Clip™ II ML (Covidien, USA). Gallbladder was dissected from liver bed carefully. Gallbladder was taken out from abdomen through the subumbilical incision.
Study: NCT04567264

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: StimRouter®, Self-activated and self-controlled neuromodulation device (Bioness Inc, CE0086).
Description: Regimen 1 (weeks 0-12): one stimulation every 2 days, for a duration of 30 minutes each.~Regimen 2 (weeks 12-24): Three stimulation treatments per week, for a duration of 30 minutes each.
Study: NCT01421095

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant FSH
Description: Each participant will recieve recombinant FSH (150 IU) intravenously
Study: NCT01633801

Intervention type: DEVICE
Group type: OTHER
Intervention: Use of high flows versus oxygen therapy
Description: Once extubation has taken place the child will be placed either on traditional oxygen therapy or high flow nasal cannulae according to randomization.

Intervention type: DEVICE
Group type: OTHER
Intervention: oxygen therapy
Description: Once extubation has taken place the child will be placed either on traditional oxygen therapy or high flow nasal cannulae according to randomization.

Intervention type: DEVICE
Group type: OTHER
Intervention: oxygen therapy
Description: Once extubation has taken place the child will be placed either on traditional oxygen therapy or high flow nasal cannulae according to randomization.
Study: NCT02801669

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Du-176b
Description: DU-176b orally administered at a dose of 15 mg once daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo orally administered once daily.
Study: NCT03161366

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rVSVΔG-ZEBOV-GP
Description: Ring vaccination with vaccination of contacts and contacts of contacts after laboratory confirmation of one Ebola Zaire case
Study: NCT03634618

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mirror Therapy
Description: Mirror therapy is the treatment method in which mental performance of movements is performed by observing the movements of the healthy extremities. In the case of mirror treatment, the mirror box is placed on a fixed floor. The mirror is positioned so that the patient's body can be fully centered and the mirror image can be seen. While the affected limb is placed on the rear side of the mirror, the firm extremity is opposite to the mirror. The patient focuses on the mirror image of the moving healthy hand and, through artificial visual feedback, perceives the affected limb as moving. The exercises are as follows: flexor tendon gliding exercises, median motor exercises, wrist and forearm ROM exercises and function-oriented exercises.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Convantional Physiotherapy
Description: The first two weeks involve only immobilisation with plaster. The next 4 weeks, patients do the exercises which follows: 15 minutes water bath, scar tissue massage, flexor tendon gliding exercises, median motor exercises, wrist flexion-extention, median nerve gliding exercise (in addition, one week after plaster removal), hand wrist stretching exercise (in addition, 2 weeks after plaster removal).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Convantional Physiotherapy
Description: The first two weeks involve only immobilisation with plaster. The next 4 weeks, patients do the exercises which follows: 15 minutes water bath, scar tissue massage, flexor tendon gliding exercises, median motor exercises, wrist flexion-extention, median nerve gliding exercise (in addition, one week after plaster removal), hand wrist stretching exercise (in addition, 2 weeks after plaster removal).
Study: NCT04550195

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BMS-986337 Placebo
Description: Specified Dose on Specified Days
Study: NCT02986490

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Blood sample
Description: Blood sample
Study: NCT01134718

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435 (G006)
Description: one morning dose of 150 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435 (F021)
Description: one morning dose of 150 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435 (G007)
Description: one morning dose of 150 mg
Study: NCT00006436

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 2 doses of rituximab every cycle: first dose on Day 1 and 2nd dose on Day 5

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Filgrastim day 6 until absolute neutrophil count (ANC) reaches 5000 after the nadir, every cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPOCH
Description: combination chemotheray: EPOCH every 3 weeks for minimum of 3 cycles and max of 6 cycles
Study: NCT01794650

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Meal composition
Study: NCT03110692

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Default initiation
Description: A default prescription template will be introduced in the palliative setting in order to reduce unnecessary daily image guided radiation.
Study: NCT00443599

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Study drug is continuously infused intravenous insulin. Suggested dose is calculated by a computerized infusion algorithm using the participant's blood sugar concentration. The insulin infusion rate is titrated to maintain normal blood sugar. Participants are eligible to receive insulin while they have an in-dwelling arterial catheter.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Participants receive standard Cardiac ICU care without tight blood glucose control.
Study: NCT01189136

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PTNS Active Treatment
Description: 34 gauge needle inserted 3cm above the medial ankle, and cables are connected to the PTNS stimulator device. Stimulation is provided, per manufacturer directions, over a 30-minute treatment period.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham treatment
Description: 34 gauge needle inserted 3cm above the medial ankle, but nonconductive cables are connected, so that no electrical stimulation is applied, over a 30-minute treatment period
Study: NCT03274206

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BLS-ILB-E710c
Description: BLS-ILB-E710c 250mg/capsule
Study: NCT03274206

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: BLS-ILB-E710c-placebo
Study: NCT03427606

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Continuous Locked Suture vs Traditional 5-points suture for Laparoscopic Sacral Colpopexy
Description: To verify if the operative time of a standard laparoscopic sacral colpopexy associated to subtotal hysterectomy for the treatment of POP could be further reduced using continuous locked suture vs traditional 5-points suture for mesh fixation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Locked Suture vs Traditional 5-points suture for Laparoscopic Sacral Colpopexy
Description: To verify if the operative time of a standard laparoscopic sacral colpopexy associated to subtotal hysterectomy for the treatment of POP could be further reduced using continuous locked suture vs traditional 5-points suture for mesh fixation
Study: NCT04550195

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BMS-986337 Placebo
Description: Specified Dose on Specified Days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BMS-986337 Placebo
Description: Specified Dose on Specified Days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BMS-986337 Placebo
Description: Specified Dose on Specified Days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Famotidine
Description: Specified Dose on Specified Days
Study: NCT02033265

Intervention type: PROCEDURE
Intervention: Brachial plexus block
Description: Ultrasound guided axillary brachial plexus block

Intervention type: PROCEDURE
Intervention: Brachial plexus block
Description: Ultrasound guided axillary brachial plexus block
Study: NCT03680170

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Working memory updating training
Description: Each training session includes four working memory updating tasks that is performed at the participants home on their computer via internet. Each training session takes about 20 minutes to perform.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo training
Description: Each training session includes four short term memory tasks that is performed at the participants home on their computer via internet. Each training session takes about 20 minutes to perform.